Form4insider filings, from the source

SEC Form 4 · accession 0000921895-26-001639

MoonLake Immunotherapeutics · MLTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
BIOTECHNOLOGY VALUE FUND L P
Director · 10% Owner
BVF PARTNERS L P/IL
Director · 10% Owner
Inc/il Bvf
Director · 10% Owner
Mark N Lampert
Director · 10% Owner
BVF Partners OS Ltd.
Director · Other
BVF I GP LLC
Director · 10% Owner
BVF II GP LLC
Director · Other
BVF GP HOLDINGS LLC
Director · 10% Owner
Period of report
Jun 17, 2026
Accepted (ET)
Jun 22, 2026 · 4:50 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001821586

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Class A Ordinary Shares, $0.0001 par valueF1,F2holding———8,302,735D
Class A Ordinary Shares, $0.0001 par valueF1,F3holding———6,599,722D
Class A Ordinary Shares, $0.0001 par valueF1,F4holding———1,039,238D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Option to BuyF1,F9,F5$19.19Jun 17, 2026A22,195A—Jun 17, 2036Class A Ordinary Shares, $0.0001 par value22,19522,195I
Option to BuyF1,F9,F6$48.83holding————Jun 5, 2035Class A Ordinary Shares, $0.0001 par value6,6826,682I
Option to BuyF1,F9,F7$42.44holding————Jun 6, 2034Class A Ordinary Shares, $0.0001 par value7,6887,688I
Option to BuyF1,F9,F8$29.18holding————Jun 8, 2033Class A Ordinary Shares, $0.0001 par value11,29711,297I

Explanation of responses

Remarks

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a Managing Director of Partners, Spike Loy, serving on the Board of Directors of the Issuer, and his agreement to transfer to Partners the economic benefit, if any, received upon the sale of any securities of the Issuer he receives in his capacity as a director of the Issuer.